carnitine and Non-alcoholic Fatty Liver Disease studies

Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Research Excerpts

Excerpt	Relevance	Reference
"Family history of obesity is the major predictor of obesity, and the metabolic abnormalities on amino acids, acylcarnitines, inflammation, insulin resistance, and NAFLD."	9.27	Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach. ( Caballero, AE; Duggirala, R; González-Chávez, A; Herrera-Rosas, A; Ibarra-González, I; León-Hernández, M; López-Alvarenga, JC; Mummidi, S; Romero-Ibarguengoitia, ME; Serratos-Canales, MF; Vadillo-Ortega, F, 2018)
"Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD."	9.19	The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014)
"Carnitine deficiency and impaired glucose tolerance (IGT) exacerbate liver steatosis."	8.12	High-fat diet-induced nonalcoholic steatohepatitis is accelerated by low carnitine and impaired glucose tolerance in novel murine models. ( Matsuura, T; Mekada, K; Nakamura, SI; Ozaki, K; Terayama, Y, 2022)
"Godex improved insulin resistance and steatosis by regulating carnitine acetyltransferase in liver in high-fat diet-fed mice."	8.02	Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. ( Hong, JH; Lee, MK, 2021)
" In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status."	7.91	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019)
"The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II."	7.80	[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. ( Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe, 2014)
"To develop a therapeutic agent for obesity-related metabolic disorders, a mixture of dietary components was prepared, including grape extract, green tea extract and l-carnitine (RGTC), and its effects on obesity, hyperlipidemia and non-alcoholic fatty liver disease examined."	7.77	A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. ( Han, SB; Kang, JS; Kim, HM; Kim, N; Lee, CW; Lee, K; Lee, KH; Lee, WK; Ly, SY; Park, HK; Park, SK; Yoon, WK; Yun, J, 2011)
"Non-alcoholic fatty liver disease (NAFLD) still has no accepted pharmacological therapy."	7.11	Hepatoprotective effect of combination of L-carnitine and magnesium-hydroxide in nonalcoholic fatty liver disease patients: a double-blinded randomized controlled pilot study. ( Abu Ahmad, N; Hazzan, R; Mazen, E; Neeman, Z; Slim, W, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the pediatric population at global level."	7.01	Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. ( Famouri, F; Hassanzadeh, A; Heidari-Beni, M; Kelishadi, R; Khademian, M; Khalilian, L; Nasri, P; Saneian, H, 2021)
"Treatment with carnitine-orotate complex improves serum ALT and may improve hepatic steatosis as assessed by CT in patients with diabetes and NAFLD."	6.80	Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. ( Bae, JC; Cho, YY; Han, KA; Ju, YC; Lee, KW; Lee, MK; Lee, WJ; Lee, WY; Park, JY; Son, HS; Woo, JT; Yoon, KH, 2015)
"L-carnitine has also been shown to improve insulin sensitivity and elevate pyruvate dehydrogenase (PDH) flux."	6.66	The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). ( Hodson, L; Neubauer, S; Pavlides, M; Savic, D, 2020)
"In light of the high prevalence of nonalcoholic fatty liver disease and obesity, treatment options for nonalcoholic steatohepatitis are of particular interest."	5.91	The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity. ( Aringazina, R; Luo, C; Samusenkov, V; Zakharova, N, 2023)
"Nonalcoholic fatty liver disease (NAFLD) has become a common liver disorder caused by lipid accumulation and insulin resistance (IR)."	5.56	A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease. ( Chang, Y; Chen, K; Fan, X; Gao, XQ; He, J; Li, H; Li, HM; Lin, XH; Shen, N; Tian, FS, 2020)
"The target of theacrine's activities on NAFLD is identified as SIRT3."	5.48	Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism. ( Gong, L; He, RR; Hong, M; Kurihara, H; Li, YF; Tian, JY; Wang, GE; Wu, YP; Yao, N; Zhai, YJ, 2018)
"Eighty percent of cases had NAFLD with increase in chemerin as severity of NAFLD increased."	5.43	Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome. ( Ebrahim, AO; Elkabbany, ZA; Hamed, AI; Hamza, RT; Shedid, AM, 2016)
"The efficacy and safety of L-carnitine supplementation on non-alcoholic fatty liver disease (NAFLD) are unclear."	5.41	Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis. ( Cai, Y; Jiao, P; Liu, A; Liu, M; Xu, Y; Yuan, Y; Zhang, Z, 2023)
"Family history of obesity is the major predictor of obesity, and the metabolic abnormalities on amino acids, acylcarnitines, inflammation, insulin resistance, and NAFLD."	5.27	Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach. ( Caballero, AE; Duggirala, R; González-Chávez, A; Herrera-Rosas, A; Ibarra-González, I; León-Hernández, M; López-Alvarenga, JC; Mummidi, S; Romero-Ibarguengoitia, ME; Serratos-Canales, MF; Vadillo-Ortega, F, 2018)
"Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD."	5.19	The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014)
"Carnitine deficiency and impaired glucose tolerance (IGT) exacerbate liver steatosis."	4.12	High-fat diet-induced nonalcoholic steatohepatitis is accelerated by low carnitine and impaired glucose tolerance in novel murine models. ( Matsuura, T; Mekada, K; Nakamura, SI; Ozaki, K; Terayama, Y, 2022)
"Godex improved insulin resistance and steatosis by regulating carnitine acetyltransferase in liver in high-fat diet-fed mice."	4.02	Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. ( Hong, JH; Lee, MK, 2021)
"Uteroplacental insufficiency-induced low birth weight (LBW) and postnatal high saturated fat/high sucrose-fructose diet (Western Diet, WD) consumption have been independently associated with the development of hepatic steatosis, while their additive effect on fatty acid, acylcarnitine and amino acid profiles in early adulthood have not been widely reported."	3.91	Western diet consumption through early life induces microvesicular hepatic steatosis in association with an altered metabolome in low birth weight Guinea pigs. ( Bureau, Y; Cheung, A; Chiu, J; Dunlop, K; Guglielmo, CG; Lee, TY; Mathers, KE; Raha, S; Regnault, TRH; Sarr, O; Zhao, L, 2019)
" In this study, we measured the serum levels of 15 acylcarnitine species of various carbon chain lengths from 2 to 18 in 241 patients with biopsy-proven NAFLD, including 23 patients with hepatocellular carcinoma (HCC), and analyzed the relationship between serum acylcarnitine profile and NAFLD status."	3.91	Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. ( Enooku, K; Fujiwara, N; Hoshida, Y; Koike, K; Kondo, M; Minami, T; Nakagawa, H; Shibahara, J; Tateishi, R, 2019)
"The article investigates the impact of complex tools fosinopril, hepadyf and ezetimibe for correction of functional state of the endothelium and changes in blood pressure in patients with nonalcoholic steatohepatitis, obesity and essential hypertension stage II."	3.80	[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. ( Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe, 2014)
"To develop a therapeutic agent for obesity-related metabolic disorders, a mixture of dietary components was prepared, including grape extract, green tea extract and l-carnitine (RGTC), and its effects on obesity, hyperlipidemia and non-alcoholic fatty liver disease examined."	3.77	A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. ( Han, SB; Kang, JS; Kim, HM; Kim, N; Lee, CW; Lee, K; Lee, KH; Lee, WK; Ly, SY; Park, HK; Park, SK; Yoon, WK; Yun, J, 2011)
"Non-alcoholic fatty liver disease (NAFLD) still has no accepted pharmacological therapy."	3.11	Hepatoprotective effect of combination of L-carnitine and magnesium-hydroxide in nonalcoholic fatty liver disease patients: a double-blinded randomized controlled pilot study. ( Abu Ahmad, N; Hazzan, R; Mazen, E; Neeman, Z; Slim, W, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the pediatric population at global level."	3.01	Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. ( Famouri, F; Hassanzadeh, A; Heidari-Beni, M; Kelishadi, R; Khademian, M; Khalilian, L; Nasri, P; Saneian, H, 2021)
"Treatment with carnitine-orotate complex improves serum ALT and may improve hepatic steatosis as assessed by CT in patients with diabetes and NAFLD."	2.80	Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. ( Bae, JC; Cho, YY; Han, KA; Ju, YC; Lee, KW; Lee, MK; Lee, WJ; Lee, WY; Park, JY; Son, HS; Woo, JT; Yoon, KH, 2015)
"L-carnitine has also been shown to improve insulin sensitivity and elevate pyruvate dehydrogenase (PDH) flux."	2.66	The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). ( Hodson, L; Neubauer, S; Pavlides, M; Savic, D, 2020)
"In light of the high prevalence of nonalcoholic fatty liver disease and obesity, treatment options for nonalcoholic steatohepatitis are of particular interest."	1.91	The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity. ( Aringazina, R; Luo, C; Samusenkov, V; Zakharova, N, 2023)
"Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disorders ranging from hepatic steatosis [excessive accumulation of triglycerides (TG)] to nonalcoholic steatohepatitis, which can progress to cirrhosis and hepatocellular carcinoma."	1.62	( Abdul Azees, PA; Barnes, JL; Das, F; Ghosh Choudhury, G; Kamat, A; Katz, MS; Pizzini, J; Shi, Y; Wang, H; Weintraub, ST; Yeh, CK; Zang, M, 2021)
"Nonalcoholic fatty liver disease (NAFLD) has become a common liver disorder caused by lipid accumulation and insulin resistance (IR)."	1.56	A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease. ( Chang, Y; Chen, K; Fan, X; Gao, XQ; He, J; Li, H; Li, HM; Lin, XH; Shen, N; Tian, FS, 2020)
"Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disorder."	1.56	L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. ( Codella, R; Luzi, L; Mollica, G; Montesano, A; Senesi, P; Terruzzi, I; Vacante, F, 2020)
"The target of theacrine's activities on NAFLD is identified as SIRT3."	1.48	Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism. ( Gong, L; He, RR; Hong, M; Kurihara, H; Li, YF; Tian, JY; Wang, GE; Wu, YP; Yao, N; Zhai, YJ, 2018)
"Eighty percent of cases had NAFLD with increase in chemerin as severity of NAFLD increased."	1.43	Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome. ( Ebrahim, AO; Elkabbany, ZA; Hamed, AI; Hamza, RT; Shedid, AM, 2016)
"Nonalcoholic fatty liver disease (NAFLD) is a globally widespread disease of increasing clinical significance."	1.42	Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. ( Aranibar, N; Cherrington, NJ; Lake, AD; Lehman-McKeeman, LD; Novak, P; Reily, MD; Robertson, DG; Shipkova, P; Vaillancourt, RR, 2015)
"Here, we report a case of sudden death in which a 10-year-old boy experienced cardiopulmonary arrest 5 min after receiving a Japanese encephalitis vaccination."	1.42	A case of sudden death after Japanese encephalitis vaccination. ( Akaza, K; Bunai, Y; Ishii, A; Nagai, A; Nishida, N; Yamaguchi, S, 2015)
"Carnitine treatment increased the mRNA expression of carnitine palmitoyltransferase 1A and peroxisome proliferator-activated receptor-γ, and carnitine-lipoic acid further augmented the mRNA expression."	1.37	Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. ( Cho, WK; Choi, HS; Hahm, JS; Jang, KS; Jeon, HJ; Jun, DW; Jun, JH; Kim, HJ; Kwon, HJ; Lee, HL; Lee, KN; Lee, MH; Lee, OY; Yoon, BC, 2011)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	20 (54.05)	24.3611
2020's	17 (45.95)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis[NCT02856555]			Phase 2	127 participants (Actual)	Interventional	2016-08-08	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Firsocostat 5 mg	70.6
Firsocostat 20 mg	71.4
Placebo	61.5

Article	Year
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD. The Journal of nutritional biochemistry, 2023, Volume: 114 Topics: Animals; Carnitine; Diet, High-Fat; Diet, Western; Dietary Fats; Fructose; Humans; Liver; Non-alcoho	2023
Mitochondrial carnitine palmitoyltransferase-II dysfunction: A possible novel mechanism for nonalcoholic fatty liver disease in hepatocarcinogenesis. World journal of gastroenterology, 2023, Mar-28, Volume: 29, Issue:12 Topics: Carcinogenesis; Carnitine; Carnitine O-Palmitoyltransferase; Fatty Acids; Glypicans; Humans; Liver;	2023
Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis. Systematic reviews, 2023, 04-29, Volume: 12, Issue:1 Topics: Adult; Carnitine; Dietary Supplements; Humans; Non-alcoholic Fatty Liver Disease; Triglycerides	2023
The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 2020, Jul-22, Volume: 12, Issue:8 Topics: Alanine Transaminase; Aspartate Aminotransferases; Cardiomyopathies; Carnitine; Dietary Supplements;	2020
Efficacy of Dietary Supplements to Reduce Liver Fat. Nutrients, 2020, Jul-31, Volume: 12, Issue:8 Topics: Adipose Tissue; Adult; Carnitine; Catechin; Dietary Supplements; Fatty Acids, Omega-3; Female; Human	2020

Article	Year
[Modification of dietary patterns in patients with non-alcoholic steatohepatitis]. Terapevticheskii arkhiv, 2022, Oct-12, Volume: 94, Issue:8 Topics: Alkaline Phosphatase; Carnitine; Cholesterol; Dietary Fiber; Female; Humans; Non-alcoholic Fatty Liv	2022
Hepatoprotective effect of combination of L-carnitine and magnesium-hydroxide in nonalcoholic fatty liver disease patients: a double-blinded randomized controlled pilot study. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:20 Topics: Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Humans; Insulins; Lipids; Liver; Magne	2022
Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. Journal of pediatric endocrinology & metabolism : JPEM, 2021, Jul-27, Volume: 34, Issue:7 Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Child, Preschool; D	2021
Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach. PloS one, 2018, Volume: 13, Issue:2 Topics: Adolescent; Adult; Amino Acids; Carnitine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Femal	2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, Volume: 155, Issue:5 Topics: Acetyl-CoA Carboxylase; Biomarkers; Carnitine; Double-Blind Method; Elasticity Imaging Techniques; F	2018
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia, 2014, Volume: 57, Issue:5 Topics: Aged; Anticholesteremic Agents; Area Under Curve; Azetidines; Biopsy; Carnitine; Cholesterol; Ezetim	2014
Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. Diabetes care, 2015, Volume: 38, Issue:7 Topics: Alanine Transaminase; Anthropometry; Blood Glucose; Capsules; Carnitine; Diabetes Mellitus, Type 2;	2015

carnitine and Non-alcoholic Fatty Liver Disease

Research Excerpts

Research

Studies (37)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percentage of Participants Experiencing Treatment-Emergent Adverse Events

Reviews

Trials

Other Studies

Authors	Studies
Terayama, Y	1
Nakamura, SI	1
Mekada, K	1
Matsuura, T	1
Ozaki, K	1
Sánchez-Quevedo, J	1
Ocampo-Rodríguez, E	1
Alvarez-Ayala, E	1
Rodríguez-López, A	1
Duarte-Vázquez, MA	1
Rosado, JL	1
Rodríguez-Fragoso, L	1
Sasunova, AN	1
Goncharov, AA	1
Morozov, SV	1
Isakov, VA	1
Hazzan, R	1
Abu Ahmad, N	1
Slim, W	1
Mazen, E	1
Neeman, Z	1
Inci, MK	3
Park, SH	3
Helsley, RN	3
Attia, SL	3
Softic, S	3
Yao, M	1
Zhou, P	1
Qin, YY	1
Wang, L	2
Yao, DF	1
Liu, A	1
Cai, Y	1
Yuan, Y	1
Liu, M	1
Zhang, Z	1
Xu, Y	1
Jiao, P	1
Zakharova, N	1
Luo, C	1
Aringazina, R	1
Samusenkov, V	1
Mollica, G	1
Senesi, P	1
Codella, R	1
Vacante, F	1
Montesano, A	1
Luzi, L	1
Terruzzi, I	1
Zhang, C	1
Bjornson, E	1
Arif, M	1
Tebani, A	1
Lovric, A	1
Benfeitas, R	1
Ozcan, M	1
Juszczak, K	1
Kim, W	1
Kim, JT	1
Bidkhori, G	1
Ståhlman, M	1
Bergh, PO	1
Adiels, M	1
Turkez, H	1
Taskinen, MR	1
Bosley, J	1
Marschall, HU	1
Nielsen, J	1
Uhlén, M	1
Borén, J	1
Mardinoglu, A	1
Chang, Y	1
Gao, XQ	1
Shen, N	1
He, J	1
Fan, X	1
Chen, K	1
Lin, XH	1
Li, HM	1
Tian, FS	1
Li, H	1
Savic, D	1
Hodson, L	1
Neubauer, S	1
Pavlides, M	1
Kilchoer, B	1
Vils, A	1
Minder, B	1
Muka, T	1
Glisic, M	1
Bally, L	1
Poulos, JE	1
Kalogerinis, PT	1
Milanov, V	1
Kalogerinis, CT	1
Poulos, EJ	1
Saneian, H	1
Khalilian, L	1
Heidari-Beni, M	1
Khademian, M	1
Famouri, F	1
Nasri, P	1
Hassanzadeh, A	1
Kelishadi, R	1
Shi, Y	1
Pizzini, J	1
Wang, H	1
Das, F	1
Abdul Azees, PA	1
Ghosh Choudhury, G	1
Barnes, JL	1
Zang, M	1
Weintraub, ST	1
Yeh, CK	1
Katz, MS	1
Kamat, A	1
Hong, JH	1
Lee, MK	2
Fujiwara, N	2
Nakagawa, H	2
Enooku, K	2
Kudo, Y	1
Hayata, Y	1
Nakatsuka, T	1
Tanaka, Y	1
Tateishi, R	2
Hikiba, Y	1
Misumi, K	1
Tanaka, M	1
Hayashi, A	1
Shibahara, J	2
Fukayama, M	1
Arita, J	1
Hasegawa, K	1
Hirschfield, H	1
Hoshida, Y	2
Hirata, Y	1
Otsuka, M	1
Tateishi, K	1
Koike, K	3
Romero-Ibarguengoitia, ME	1
Vadillo-Ortega, F	1
Caballero, AE	1
Ibarra-González, I	1
Herrera-Rosas, A	1
Serratos-Canales, MF	1
León-Hernández, M	1
González-Chávez, A	1
Mummidi, S	1
Duggirala, R	1
López-Alvarenga, JC	1
Wang, GE	1
Li, YF	1
Zhai, YJ	1
Gong, L	1
Tian, JY	1
Hong, M	1
Yao, N	1
Wu, YP	1
Kurihara, H	1
He, RR	1
Loomba, R	1
Kayali, Z	1
Noureddin, M	1
Ruane, P	1
Lawitz, EJ	1
Bennett, M	1
Harting, E	1
Tarrant, JM	1
McColgan, BJ	1
Chung, C	1
Ray, AS	1
Subramanian, GM	1
Myers, RP	1
Middleton, MS	1
Lai, M	1
Charlton, M	1
Harrison, SA	1
Xu, X	1
Zhu, XP	1
Bai, JY	1
Xia, P	1
Li, Y	1
Lu, Y	1
Li, XY	1
Gao, X	1
Sarr, O	1
Mathers, KE	1
Zhao, L	1
Dunlop, K	1
Chiu, J	1
Guglielmo, CG	1
Bureau, Y	1
Cheung, A	1
Raha, S	1
Lee, TY	1
Regnault, TRH	1
Phowthongkum, P	1
Suphapeetiporn, K	1
Shotelersuk, V	1
Kondo, M	1
Minami, T	1
Takeshita, Y	1
Takamura, T	1
Honda, M	1
Kita, Y	1
Zen, Y	1
Kato, K	1
Misu, H	1
Ota, T	1
Nakamura, M	1
Yamada, K	1
Sunagozaka, H	1
Arai, K	1
Yamashita, T	1
Mizukoshi, E	1
Kaneko, S	1
Ishikawa, H	1
Takaki, A	1
Tsuzaki, R	1
Yasunaka, T	1
Shimomura, Y	1
Seki, H	1
Matsushita, H	1
Miyake, Y	1
Ikeda, F	1
Shiraha, H	1
Nouso, K	1
Yamamoto, K	1
Lake, AD	1
Novak, P	1
Shipkova, P	1
Aranibar, N	1
Robertson, DG	1
Reily, MD	1
Lehman-McKeeman, LD	1
Vaillancourt, RR	1
Cherrington, NJ	1
Khukhlina, OS	1
Mandryk, OIe	1
Drozd, VIu	1
Haĭdychuk, VS	1
Kosar, LIu	1
Bunai, Y	1
Ishii, A	1
Akaza, K	1
Nagai, A	1
Nishida, N	1
Yamaguchi, S	1
Bae, JC	1
Lee, WY	1
Yoon, KH	1
Park, JY	1
Son, HS	1
Han, KA	1
Lee, KW	1
Woo, JT	1
Ju, YC	1
Lee, WJ	1
Cho, YY	1
Patterson, RE	1
Kalavalapalli, S	1
Williams, CM	1
Nautiyal, M	1
Mathew, JT	1
Martinez, J	1
Reinhard, MK	1
McDougall, DJ	1
Rocca, JR	1
Yost, RA	1
Cusi, K	1
Garrett, TJ	1
Sunny, NE	1
Morris, EM	1
Meers, GM	1
Koch, LG	1
Britton, SL	1
Fletcher, JA	1
Fu, X	1
Shankar, K	1
Burgess, SC	1
Ibdah, JA	1
Rector, RS	1
Thyfault, JP	1
Hamza, RT	1
Elkabbany, ZA	1
Shedid, AM	1
Hamed, AI	1
Ebrahim, AO	1
Kang, JS	1
Lee, WK	1
Yoon, WK	1
Kim, N	1
Park, SK	2
Park, HK	1
Ly, SY	1
Han, SB	1
Yun, J	1
Lee, CW	1
Lee, K	1
Lee, KH	1
Kim, HM	1
Bjørndal, B	1
Burri, L	1
Wergedahl, H	1
Svardal, A	1
Bohov, P	1
Berge, RK	1
Jun, DW	1
Cho, WK	1
Jun, JH	1
Kwon, HJ	1
Jang, KS	1
Kim, HJ	1
Jeon, HJ	1
Lee, KN	1
Lee, HL	1
Lee, OY	1
Yoon, BC	1
Choi, HS	1
Hahm, JS	1
Lee, MH	1

Article	Year
High-fat diet-induced nonalcoholic steatohepatitis is accelerated by low carnitine and impaired glucose tolerance in novel murine models. Laboratory investigation; a journal of technical methods and pathology, 2022, Volume: 102, Issue:6 Topics: Alloxan; Animals; Carcinogenesis; Carnitine; Diet, High-Fat; Disease Models, Animal; Glucose Intoler	2022
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats. BMC pharmacology & toxicology, 2022, 09-29, Volume: 23, Issue:1 Topics: Animals; Carnitine; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fructose; Glucose; Glycogen	2022
The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity. Lipids in health and disease, 2023, Jul-12, Volume: 22, Issue:1 Topics: Carnitine; Diet, Reducing; Humans; Non-alcoholic Fatty Liver Disease; Obesity	2023
L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:3 Topics: Animals; Carnitine; Choline Deficiency; Diet; Dietary Supplements; Disease Models, Animal; Disease P	2020
The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. Molecular systems biology, 2020, Volume: 16, Issue:4 Topics: Acetylcysteine; Adult; Animals; Carnitine; Dietary Supplements; Drug Therapy, Combination; Healthy V	2020
A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:13 Topics: Adult; Biomarkers; Carnitine; Case-Control Studies; Chromatography, High Pressure Liquid; Female; Hu	2020
The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease. Journal of dietary supplements, 2022, Volume: 19, Issue:3 Topics: Blood Glucose; Carnitine; Glucose; Humans; Insulin; Insulin Resistance; Liver; Metabolic Syndrome; N	2022
American journal of physiology. Endocrinology and metabolism, 2021, 07-01, Volume: 321, Issue:1 Topics: Adrenergic beta-2 Receptor Agonists; Animals; Carnitine; Fatty Liver; Formoterol Fumarate; Gene Expr	2021
Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. Diabetes & metabolism journal, 2021, Volume: 45, Issue:6 Topics: Animals; Body Weight; Carnitine; Carnitine O-Acetyltransferase; Diabetes Mellitus, Type 2; Humans; I	2021
CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut, 2018, Volume: 67, Issue:8 Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase; Case-C	2018
Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism. Metabolism: clinical and experimental, 2018, Volume: 85 Topics: Animals; Apolipoproteins E; Carnitine; Diet, High-Fat; Energy Metabolism; Male; Mice; Mice, Knockout	2018
Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:6 Topics: Acetylation; Acyl-CoA Dehydrogenase, Long-Chain; Animals; Berberine; Carnitine; Diet, High-Fat; Drug	2019
Western diet consumption through early life induces microvesicular hepatic steatosis in association with an altered metabolome in low birth weight Guinea pigs. The Journal of nutritional biochemistry, 2019, Volume: 67 Topics: Animals; Animals, Newborn; Birth Weight; Carnitine; Diet, Western; Fatty Acids; Female; Guinea Pigs;	2019
Carnitine palmitoyl transferase 1A deficiency in an adult with recurrent severe steato hepatitis aggravated by high pathologic or physiologic demands: A roller-coaster for internists. Clinical and molecular hepatology, 2019, Volume: 25, Issue:4 Topics: Adult; Anti-Bacterial Agents; Carnitine; Carnitine O-Palmitoyltransferase; Escherichia coli Infectio	2019
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Scientific reports, 2019, 07-23, Volume: 9, Issue:1 Topics: Adult; Age Factors; Aged; Carcinoma, Hepatocellular; Carnitine; Disease Progression; Female; Humans;	2019
L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PloS one, 2014, Volume: 9, Issue:7 Topics: Animals; Carnitine; Dietary Fats; Disease Models, Animal; Male; Mice; Mitochondria, Liver; Non-alcoh	2014
Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino acids, 2015, Volume: 47, Issue:3 Topics: Carnitine; Female; Gene Expression Profiling; Humans; Isoleucine; Leucine; Male; Metabolomics; Non-a	2015
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2014, Volume: 67, Issue:2 Pt 2 Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular;	2014
A case of sudden death after Japanese encephalitis vaccination. Legal medicine (Tokyo, Japan), 2015, Volume: 17, Issue:4 Topics: Anaphylaxis; Arrhythmias, Cardiac; Autopsy; C-Reactive Protein; Carnitine; Cause of Death; Child; De	2015
Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. American journal of physiology. Endocrinology and metabolism, 2016, Apr-01, Volume: 310, Issue:7 Topics: Animals; Carbon Isotopes; Carnitine; Ceramides; Chromatography, Liquid; Citric Acid Cycle; Dietary F	2016
Aerobic capacity and hepatic mitochondrial lipid oxidation alters susceptibility for chronic high-fat diet-induced hepatic steatosis. American journal of physiology. Endocrinology and metabolism, 2016, 10-01, Volume: 311, Issue:4 Topics: Aerobiosis; Animals; Carnitine; Citric Acid Cycle; Diet, High-Fat; Disease Susceptibility; Fatty Aci	2016
Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome. Archives of medical research, 2016, Volume: 47, Issue:7 Topics: Adolescent; Antioxidants; Biomarkers; Carnitine; Case-Control Studies; Chemokines; Child; Child, Pre	2016
A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. Phytotherapy research : PTR, 2011, Volume: 25, Issue:12 Topics: Adipose Tissue; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Carnitine;	2011
Dietary supplementation of herring roe and milt enhances hepatic fatty acid catabolism in female mice transgenic for hTNFα. European journal of nutrition, 2012, Volume: 51, Issue:6 Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents; Carnitine; Cytokines; Diet, High-Fat; Diet	2012
Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:9 Topics: Adenosine Triphosphate; Animals; Apoptosis; Carnitine; Carnitine O-Palmitoyltransferase; Choline Def	2011